{"id":"io102-io103","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (colitis, hepatitis, pneumonitis)"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL6068401","moleculeType":"Protein","molecularWeight":"2318.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IO102-IO103 combines IO102 (a personalized neoantigen vaccine) with IO103 (an anti-CTLA-4 checkpoint inhibitor) to enhance anti-tumor immunity. The vaccine targets neoantigens derived from individual patient tumors, while the checkpoint inhibitor removes immune suppression, allowing T cells to mount a more robust response against cancer cells.","oneSentence":"IO102-IO103 is a personalized neoantigen vaccine designed to activate the immune system against patient-specific tumor mutations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:55.538Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (adjuvant setting)"},{"name":"Non-small cell lung cancer (adjuvant setting)"}]},"trialDetails":[{"nctId":"NCT05843448","phase":"PHASE1","title":"IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-04-19","conditions":"High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT05912244","phase":"PHASE2","title":"A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-06-09","conditions":"Melanoma","enrollment":43},{"nctId":"NCT04445064","phase":"PHASE2","title":"Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-08-14","conditions":"Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma","enrollment":17},{"nctId":"NCT05155254","phase":"PHASE3","title":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","status":"ACTIVE_NOT_RECRUITING","sponsor":"IO Biotech","startDate":"2022-05-17","conditions":"Metastatic Melanoma, Unresectable Melanoma","enrollment":407},{"nctId":"NCT03047928","phase":"PHASE1, PHASE2","title":"Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2018-02-22","conditions":"Metastatic Melanoma","enrollment":48},{"nctId":"NCT05077709","phase":"PHASE2","title":"IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"IO Biotech","startDate":"2022-02-14","conditions":"Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder","enrollment":63},{"nctId":"NCT05280314","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","status":"RECRUITING","sponsor":"IO Biotech","startDate":"2023-12-21","conditions":"Melanoma, Squamous Cell Carcinoma of Head and Neck","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IO102-IO103","genericName":"IO102-IO103","companyName":"IO Biotech","companyId":"io-biotech","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IO102-IO103 is a personalized neoantigen vaccine designed to activate the immune system against patient-specific tumor mutations. Used for Melanoma (adjuvant setting), Non-small cell lung cancer (adjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}